Greenwich LifeSciences Files Patent Claims to Double GP2 Market to 88,000 Patients
Greenwich LifeSciences filed new patent claims based on FLAMINGO-01 Phase III open-label data showing statistically significant immune response and an 80% reduction in recurrence across non-HLA-A*02 patients, potentially doubling the addressable GP2 market to 88,000 patients annually in the US and Europe. If granted, protection runs to 2045.
1. Patent Claim Update
Greenwich LifeSciences has filed new patent claims based on preliminary FLAMINGO-01 open-label data showing statistically significant immune response and recurrence rate reductions in non-HLA-A02 patients. The claims expand clinical benefit beyond HLA-A02 arms, potentially doubling the GP2 market to 88,000 patients per year in the US and Europe, and if granted would protect the invention through 2045.
2. FLAMINGO-01 Trial Data
FLAMINGO-01 is a Phase III randomized trial evaluating Fast Track designated GLSI-100 in HER2-positive breast cancer patients. Non-HLA-A02 arm has enrolled 250 patients, with preliminary data showing an approximately 80% reduction in recurrence after the Primary Immunization Series, mirroring Phase IIb results and supporting combined analysis of HLA-A02 and non-HLA-A*02 cohorts.
3. Market and Financial Implications
The company projects that combined enrollment of HLA-A02 and non-HLA-A02 patients will enhance statistical power and support applications for both groups, with GP2 market potential rising to a $10 billion annual revenue opportunity. Patent prosecution success could secure market exclusivity until 2045, bolstering long-term valuation and competitive positioning.